Cerevance launched with new technology, drug portfolio and $36m in cash to tackle brain diseases
World Pharma Today | February 20, 2017
Takeda Pharmaceutical Company Limited and Lightstone Ventures announced the launch of Cerevance, a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric disorders. The company will use a new technology, created in the Howard Hughes Medical Institute laboratory of Nathaniel Heintz, Ph.D. at the Rockefeller University.